

# INFECTION PREVENTION STRATEGIES FOR THE ASC PHARMACY - 2015

Christopher M. Dembny R.Ph.



## With a Little Other Compliance Added In



## Biography

- ❑ Christopher M. Dembny R.Ph.
- ❑ Licensed pharmacist in Texas for 30 years
- ❑ Consultant pharmacist for surgery centers for 20 years
- ❑ Exclusively practicing in surgery centers and surgical hospitals and ERs for 15 years
- ❑ Currently consulting for > 70 ASCs
- ❑ Current Board Member Texas State Board of Pharmacy

**Question #1: T or F**

- The United States Pharmacopiea authored USP 797 and has regulatory oversight of surgery centers.

---

---

---

---

---

---

---

**Question #2: T or F**

- Compounding pharmacies are your best option to provide you compounded sterile products.

---

---

---

---

---

---

---

**Question #3: T or F**

- DEA requires two licensed personnel to witness waste of controlled substances.

---

---

---

---

---

---

---

**Question #4: T or F**

- Per DEA, you may dispose of controlled substance waste by mixing with objectionable substances (ipecac) or absorbents (kitty litter).

---

---

---

---

---

---

---

**Question #5: T or F**

- DEA requires controlled substances to be stored in double locking cabinet.

---

---

---

---

---

---

---

**Infection Control**

- Infection control is a hot topic among all of the regulatory and accreditation agencies
- Infections are a major problem in hospitals
- Hospital-Acquired Infections Cost \$10 Billion a Year: Study --- US News 9/3/13
- One out of every 20 patients who are admitted to a hospital will fall victim to an infection they pick up while there, according to the U.S. Centers for Disease Control and Prevention
- (US News 9/3/13)

---

---

---

---

---

---

---

## Hospital?

- ❑ Four surgeons performed more than 10,000 orthopaedic surgeries in a multispecialty and single specialty ambulatory setting over 8 years. These procedures were reviewed for postoperative deep infection within one year of initial operation.

---

---

---

---

---

---

---

## RESULTS:

- ❑ The post-surgical deep infection rate in a multi-specialty ASC was **0.81%** for 2867 operations compared with a rate of **0.38%** for 7311 operations performed in a single specialty ASC ( $p = 0.007$ ).
- ❑ PubMed: J Orthop 9/5/13

---

---

---

---

---

---

---

## Who Has Oversight?

- ❑ FDA
- ❑ CMS
- ❑ Department of State Health Services
- ❑ State Board of Pharmacy (some states)
- ❑ **The Joint Commission**
- ❑ **AAAHC**
- ❑ **AAAASF - DNV - others**
- ❑ **Why green? \$\$\$**

---

---

---

---

---

---

---

### Single-Dose Vial

- ❑ A single-dose or single-use vial is a vial of liquid medication intended for parenteral administration (injection or infusion) that is meant for use in a single patient for a single case/procedure/injection. (AAAHC)

---

---

---

---

---

---

---

### Single-Dose Vial

- ❑ Single-dose or single-use vials are labeled as such by the manufacturer and typically lack an antimicrobial preservative.
- ❑ (AAAHC)
- ❑ (Single-dose; single-patient; preservative-free; PF; MPF)

---

---

---

---

---

---

---

### Multiple-Dose Vial

- ❑ A multiple-dose vial is a vial of liquid medication intended for parenteral administration (injection or infusion) that contains more than one dose of medication. Multiple-dose vials are labeled as such by the manufacturer and typically contain an antimicrobial preservative to help prevent the growth of **bacteria** (AAAHC), not fungi or virus.

---

---

---

---

---

---

---

## Single-Dose Vial

- Use a single-dose/single-use vial for a single patient during the course of a single procedure.
- Discard the vial after this single use; used vials should never be returned to stock on clinical units, drug carts, anesthesia carts, etc. (TJC)
- Identify SDV/MDV

---

---

---

---

---

---

---

## Single-Dose Vial

- If a single-dose/single-use vial must be entered more than once during a single procedure for a single patient to achieve safe and accurate titration of dosage, use a new needle and new syringe for each entry. (TJC)

---

---

---

---

---

---

---

## Single-Dose Vial

- Under certain conditions, it is permissible to repack single-dose vials or single-use vials (collectively referred to in this memorandum as "SDVs") into smaller doses, each intended for a single patient. (CMS)
- propofol -

---

---

---

---

---

---

---

## Single-Dose Vial

- ❑ Administering drugs from one SDV to multiple patients without adhering to USP <797> standards is not acceptable under CMS infection control regulations. (CMS)
- ❑ Must be done in an ISO class 5 environment by someone compliant with USP 797. [compounding pharmacy-outsourcing facility] **check your state rules.**

---

---

---

---

---

---

---

## Multiple-Dose Vials

- ❑ Only vials clearly labeled by the manufacturer for multiple-dose use can be used more than once.
- ❑ Limit the use of a multiple-dose vial to only a single patient, whenever possible, to reduce the risk of contamination. (TJC)

---

---

---

---

---

---

---

## Multiple-Dose Vials

- ❑ Disinfect the vial's rubber septum before piercing by wiping (and using friction) with a **sterile** 70 percent isopropyl alcohol "ethyl/ethanol alcohol, lodophor" or other approved antiseptic swab.
- ❑ Allow the septum to dry before inserting a needle or other device into the vial. (TJC)

---

---

---

---

---

---

---

## Multiple-Dose Vials

- Once a **multiple-dose** vial is punctured, it should be assigned a "beyond-use" date. The beyond-use date for an opened or entered (e.g., needle punctured) multiple-dose container with antimicrobial preservatives is **28** days, unless otherwise specified by the manufacturer. (TJC)

## Multiple-Dose Vials

- ❑ **Multiple-dose medications used for more than one patient are stored and accessed away from the immediate areas where direct patient contact occurs. (CMS infection control worksheet)**  
[http://www.cms.gov/Regulations-and-guidance/Guidance/Manuals/downloads/som107\\_exhibit\\_351.pdf](http://www.cms.gov/Regulations-and-guidance/Guidance/Manuals/downloads/som107_exhibit_351.pdf)

## Compounded Sterile Products

## Definition: Low Risk Compounding

- (I) Single volume transfers of sterile dosage forms from ampules, bottles, bags, and vials using sterile syringes with sterile needles, other administration devices, and other sterile containers. The solution content of ampules shall be passed through a sterile filter (**filter needle**) to remove any particles. (TSBP Rules)

## Compounded Sterile Products

- (II) Simple aseptic measuring and transferring with not more than three packages of manufactured sterile products, including an infusion or diluent solution to compound drug admixtures and nutritional solutions. (TSBP Rules)

---

---

---

---

---

---

---

## Compounded Sterile Products

- Always use aseptic technique and all of the techniques described earlier.
- USP 797 is a long and detailed tome which you don't want to study enough to comprehend and can't comply with in the ASC.
- EXCEPT:
  - (CMD)

---

---

---

---

---

---

---

## Compounded Sterile Products

- **Immediate Use Exemption**
- Compounded sterile products are exempted from all other requirements of USP 797 if administration is **begun to the patient within 1 hour** and **continues no longer than 24 hours**.
- (CMD)

---

---

---

---

---

---

---

## Immediate Use Exemption

- IMMEDIATE USE COMPOUNDED STERILE PRODUCTS (CSPs)
- For the purpose of emergency or immediate patient care, CSPs are exempted from the requirements described in this chapter for Low-Risk Level, Medium-Risk Level, and High-Risk Level CSPs when all of the following criteria are met:

---

---

---

---

---

---

---

## Immediate Use Exemption

1. Only simple aseptic measuring and transfer manipulations are performed with not more than three (3) sterile nonhazardous commercial drug and diagnostic radiopharmaceutical drug products, including an infusion or diluent solution.

---

---

---

---

---

---

---

## Immediate Use Exemption

2. Unless required for the preparation, the preparation procedure occurs continuously without delays or interruptions and does not exceed 1 hour.

---

---

---

---

---

---

---

### Immediate Use Exemption

3. At no point during preparation and prior to administration are critical surfaces and ingredients of the CSP directly exposed to contact contamination such as human touch, cosmetic flakes or particulates, blood, human body substances (excretions and secretions e.g., nasal and oral), and non-sterile inanimate sources.

---

---

---

---

---

---

---

### Immediate Use Exemption

4. Administration **begins** not later than one (1) hour following the start of preparing the CSP.

---

---

---

---

---

---

---

### Immediate Use Exemption

- When the CSP is not administered by the person who prepared it, or its administration is not witnessed by the person who prepared it, the CSP shall bear a label listing patient identification information such as name and identification number(s), the names and amounts of all ingredients, the name or initials of the person who prepared the CSP, and the exact 1-hour beyond-use time and date.

---

---

---

---

---

---

---

## Immediate Use Exemption

- If administration has not begun within one (1) hour following the start of preparing the CSP, the CSP is promptly and safely discarded. Immediate Use CSPs shall not be stored for later use.
- (USP 797)

---

---

---

---

---

---

---

## Safe Injection Practices

- 1. Use aseptic technique to avoid contamination of sterile injection equipment.
- 2. Needles, cannulae, and syringes are sterile, single-use items. They should never be reused for another patient nor to access a medication or solution that might be used for a subsequent patient.

---

---

---

---

---

---

---

## Safe Injection Practices

- 3. Do not administer medications from a syringe to multiple patients, even if the needle or cannula on the syringe is changed.
- 4. Use fluid infusion and administration sets for one patient only and dispose appropriately after use. Consider a syringe or needle/cannula contaminated once it has been used to enter or connect to a patient's intravenous infusion bag or administration set.

---

---

---

---

---

---

---

## Safe Injection Practices

- 5. Use single-dose vials for parenteral medications whenever possible.
- 6. Do not administer medications from single-dose vials or ampules to multiple patients or combine leftover contents for later use.
- 7. If multiple-dose vials must be used, both the needle or cannula and syringe used to access the multiple-dose vial must be sterile.

---

---

---

---

---

---

---

## Safe Injection Practices

- 8. Do not keep multiple-dose vials in the immediate patient treatment area. Store multiple-dose vials in accordance with the manufacturer's recommendations. Discard multiple-dose vials if sterility is compromised or questionable.
- 9. Do not use bags or bottles of intravenous solution as a common source of supply for multiple patients. (these are not MDV)
- (CDC)

---

---

---

---

---

---

---

## Questions?

- Questions on sterile products??????

---

---

---

---

---

---

---

## Compounding Pharmacies?

- ❑ Solution or more problems?

---

---

---

---

---

---

---

## Are Compounding Pharmacies a Viable Answer?

- Maybe???
- But choose carefully.
- Get approval from Med Exec.
- The cheapest isn't always the best.
- The cheapest isn't always the cheapest -- Ask those who used NECC.

---

---

---

---

---

---

---

## Outsourcing Facilities?

- FDA now says that pharmacies may no longer compound items for "office use compounding" without being patient specific.
- Many state boards of pharmacy consider "office use" compounding part of the practice of pharmacy.

---

---

---

---

---

---

---

## Picking a Good Compounder

### A. Look for accreditation:

- Pharmacy Compounding Accreditation Board (PCAB)
- An independent accreditation organization
- FDA registration (outsourcing facility)
- Can't ensure everything is perfect

---

---

---

---

---

---

---

## Picking a Good Compounder

### B. Independent assessment

- Consultant pharmacist can be a resource
- International Association of Compounding Pharmacists (IACP) <http://www.iacprx.org/>
- <http://www.iacprx.org/associations/13421/files/CPAQ%20REV%20with%20updated%20member%20number%20October%202012.pdf>
- This is the assessment tool from IACP

---

---

---

---

---

---

---

## Picking a Good Compounder

### C. Consultant Pharmacist Assessment

### D. I would use in-state compounders

---

---

---

---

---

---

---

## Picking a Good Compounder

E. Ask for independent analysis

1. Sterility
  - a. Bacterial
  - b. Fungal
2. Quantitative Analysis

---

---

---

---

---

---

---

## Outsourcing Facilities

- Also known as 503 B Pharmacies
- Must comply with CGMP requirements
- Will be inspected by FDA according to a risk-based schedule
- Must meet certain other conditions, such as reporting adverse events and providing FDA with certain information about the products they compound

---

---

---

---

---

---

---

## Outsourcing Facilities



---

---

---

---

---

---

---

## Outsourcing Facilities

- At this time (11/14), there are 55 of these listed on the FDA web site
- <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm378645.htm>
- Only 37 of these have been inspected at this time

---

---

---

---

---

---

---

## Outsourcing Facilities

- All but two of the inspected facilities received a FDA-483 (notice of deficiencies)
- Range from 3 to 20 pages (or more)

---

---

---

---

---

---

---

## Outsourcing Facilities

- Outsourcing facilities may soon be your only choice for compounded sterile products
- This is an ongoing issue that could be a turf war between FDA and Boards of Pharmacy
- No clear direction at this point
- Questions on outsourcing facilities?

---

---

---

---

---

---

---

# Drugs

---



---



---



---



---



---



---

## Controlled Substances

### Required Documentation:

- 1. Biannual controlled substance inventory (once every two years) (TX-annual)
- 2. CII invoices with DEA 222... or CSOS In separate file (signed by person receiving)
- 3. Power of attorney to sign DEA 222
- 4. CIII-V invoices (separate) (signed)
- 5. Controlled substance **reproducible** audit trail

---



---



---



---



---



---



---

## Controlled Substances

BLANK DEA FORM-222  
U.S. OFFICIAL ORDER FORM - SCHEDULES I & II

Business Name of Purchaser	Business Address of Purchaser	Phone Number of Purchaser	State of Purchaser	Zip Code of Purchaser	Phone Number of Person Receiving	Date of Purchase
McKesson Medical Surgical		4260 Patricia Drive, Suite 100		TX		03/20/03
Grapevine, TX		TX		76051		03/20/03
THIS FORM IS TO BE FILLED IN BY PURCHASER						
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31	32	33	34	35
36	37	38	39	40	41	42
43	44	45	46	47	48	49
50	51	52	53	54	55	56
57	58	59	60	61	62	63
64	65	66	67	68	69	70
71	72	73	74	75	76	77
78	79	80	81	82	83	84
85	86	87	88	89	90	91
92	93	94	95	96	97	98
99	100	101	102	103	104	105
106	107	108	109	110	111	112
113	114	115	116	117	118	119
120	121	122	123	124	125	126
127	128	129	130	131	132	133
134	135	136	137	138	139	140
141	142	143	144	145	146	147
148	149	150	151	152	153	154
155	156	157	158	159	160	161
162	163	164	165	166	167	168
169	170	171	172	173	174	175
176	177	178	179	180	181	182
183	184	185	186	187	188	189
190	191	192	193	194	195	196
197	198	199	200	201	202	203
204	205	206	207	208	209	210
211	212	213	214	215	216	217
218	219	220	221	222	223	224
225	226	227	228	229	230	231
232	233	234	235	236	237	238
239	240	241	242	243	244	245
246	247	248	249	250	251	252
253	254	255	256	257	258	259
260	261	262	263	264	265	266
267	268	269	270	271	272	273
274	275	276	277	278	279	280
281	282	283	284	285	286	287
288	289	290	291	292	293	294
295	296	297	298	299	300	301
302	303	304	305	306	307	308
309	310	311	312	313	314	315
316	317	318	319	320	321	322
323	324	325	326	327	328	329
330	331	332	333	334	335	336
337	338	339	340	341	342	343
344	345	346	347	348	349	350
351	352	353	354	355	356	357
358	359	360	361	362	363	364
365	366	367	368	369	370	371
372	373	374	375	376	377	378
379	380	381	382	383	384	385
386	387	388	389	390	391	392
393	394	395	396	397	398	399
400	401	402	403	404	405	406
407	408	409	410	411	412	413
414	415	416	417	418	419	420
421	422	423	424	425	426	427
428	429	430	431	432	433	434
435	436	437	438	439	440	441
442	443	444	445	446	447	448
449	450	451	452	453	454	455
456	457	458	459	460	461	462
463	464	465	466	467	468	469
470	471	472	473	474	475	476
477	478	479	480	481	482	483
484	485	486	487	488	489	490
491	492	493	494	495	496	497
498	499	500	501	502	503	504
505	506	507	508	509	510	511
512	513	514	515	516	517	518
519	520	521	522	523	524	525
526	527	528	529	530	531	532
533	534	535	536	537	538	539
540	541	542	543	544	545	546
547	548	549	550	551	552	553
554	555	556	557	558	559	550
551	552	553	554	555	556	557
558	559	550	551	552	553	554
555	556	557	558	559	550	551
552	553	554	555	556	557	558
559	550	551	552	553	554	555
556	557	558	559	550	551	552
553	554	555	556	557	558	559
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553	554	555	556	557	558	559
554	555	556	557	558	559	550
555	556	557	558	559	550	551
556	557	558	559	550	551	552
557	558	559	550	551	552	553
558	559	550	551	552	553	554
559	550	551	552	553	554	555
550	551	552	553	554	555	556
551	552	553	554	555	556	557
552	553	554	555	556	557	558
553						

## Controlled Substances

## *Reproducible Audit Trail*

- A. Track in --- all invoices
- B. Monthly summary from wholesaler
- C. Valid administration records
- D. Witness of Waste
  - 1. DEA non-retrievable
  - 2. OSHA – EPA – transport – destruction

## Controlled Substances

## *Reproducible Audit Trail*

- E. Transfer of drug to another registrant (5% rule) proper documentation\*\*\*\*
- F. Documentation of destruction (reverse management) \*\*\*\*\*
- **Document everything in and everything out**  
– cradle to grave \*\*\*\*\*

## Controlled Substances

- **Controlled substance administration records**
- Date and time of administration
- Patient name
- Drug and dose administered
- **Signature** of person administering \*\*\*
- Amount of Waste (if any) and **signature of person** witnessing waste
- Name of ordering practitioner
- **Must be maintained separately from chart**

## Controlled Substances

- Ordering:
- CII --- DEA 222 or CSOS (power of attorney)
- CIII-V --- order like dangerous drugs
- Files for invoices --- signed
- Continual inventory – (counts?)
- Administration records

## Controlled Substances

Controlled Substance Administration Record

Date: \_\_\_\_\_

sheet # \_\_\_\_\_

Start of day removal Signed out by:	From date checked	To date checked	If Other checked	If Other checked	Checked out to whom
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Admits by (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Ward visitors (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Admits by (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Ward visitors (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Admits by (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Ward visitors (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Admits by (signature)
Patient Sticker	From date checked	From date checked	From date checked	From date checked	Ward visitors (signature)
End of day return	From date checked	From date checked	From date checked	From date checked	Return to stock (signature)

## Controlled Substances

- **Theft or loss**

- DEA 106 – now online only
- Theft or “significant loss”
- Check state and local requirements
- TX - DEA, DPS, TDSHS, TSBP, local police

---

---

---

---

---

---

---

## Controlled Substances

- **Adequate Security**

- Double locked?
- Bolted to wall?
- Security system? (camera)
- Metal cabinet?
- Steel safe?

---

---

---

---

---

---

---

## Controlled Substance Questions??????

---

---

---

---

---

---

---

## Pharmacy Compliance

- A. All drugs are secured to prevent unauthorized access.
- B. Licenses available and up to date
- C. Storage temperature adequate – thermometer (Recording? Accurate?)
- D. No expired medications
- E. Invoices

---

---

---

---

---

---

---

## Pharmacy Compliance

- F. Recall notices
- G. Drug storage (MDV)
- H. Pharmacy Policies and Procedures
- I. Chart review

---

---

---

---

---

---

---

## Pharmacy Compliance

### • Chart Review

- A. Allergies – current and consistent and what reaction
- B. Potential for allergic reaction
- C. Potential for drug interaction
- D. Potential for adverse reaction

---

---

---

---

---

---

---

## Pharmacy Compliance

- **Chart Review**

- E. Valid orders for drugs administered
- F. Documentation of administration or drugs that were ordered
- G. Anesthesia/sedation record matches controlled substance administration record

---

---

---

---

---

---

---

## Miscellaneous

- A. Hydrocodone CII

- Make sure to order UD on DEA 222

- B. Tramadol is CIV

- Make sure to inventory on biennial inventory

---

---

---

---

---

---

---

## Question 1: T or F

- The United States Pharmacopiea authored USP 797 and has regulatory oversight of surgery centers

---

---

---

---

---

---

---

**Question 2: T or F**

- Compounding pharmacies are your best option to provide you compounded sterile products

---

---

---

---

---

---

**Question 3: T or F**

- DEA requires two licensed personnel to witness waste of controlled substances

---

---

---

---

---

---

**Question 4: T or F**

- Per DEA, you may dispose of controlled substance waste by mixing with objectionable substances (ipecac) or absorbents (kitty litter).

---

---

---

---

---

---

**Question 5: T or F**

- DEA requires controlled substances to be stored in double locking cabinet.

---

---

---

---

---

---

---

**Review Questions**

- All answers are False

---

---

---

---

---

---

---

**Questions?????**

---

---

---

---

---

---

---

## Contact Information

□ Christopher M. Dembny R.Ph  
□ [Cdembny@tx.rr.com](mailto:Cdembny@tx.rr.com)

Thank you!